{"id":"risperidone-divalproex","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Metabolic effects (hyperglycemia, dyslipidemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone blocks dopamine D2 receptors to reduce psychotic symptoms and agitation, while divalproex stabilizes mood through multiple mechanisms including GABA enhancement and histone deacetylase inhibition. The combination targets both acute psychotic symptoms and mood stabilization in bipolar disorder.","oneSentence":"This combination uses risperidone (a dopamine antagonist) and divalproex (a histone deacetylase inhibitor and mood stabilizer) together to treat bipolar disorder and related psychiatric conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:15.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder (acute mania and maintenance treatment)"},{"name":"Schizophrenia with mood instability"}]},"trialDetails":[{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT04218981","phase":"NA","title":"Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-01-15","conditions":"Common Mental Disorder","enrollment":200},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT02870283","phase":"PHASE4","title":"Cost- Effectiveness and Quality of Life Assessment in Mood Disorder","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2010-05","conditions":"Bipolar Disorder","enrollment":107},{"nctId":"NCT00221403","phase":"PHASE3","title":"Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02456454","phase":"PHASE3","title":"Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2006-01","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT01977300","phase":"PHASE3","title":"Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01","conditions":"Bipolar I Disorder","enrollment":159},{"nctId":"NCT00176202","phase":"PHASE3","title":"Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2003-04","conditions":"Bipolar Disorder","enrollment":65},{"nctId":"NCT00048802","phase":"PHASE4","title":"Treatment and Outcome of Early Onset Bipolar Disorder","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2002-08","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT00208819","phase":"PHASE4","title":"A Comparison of Two Standard Therapies in the Management of Dementia With Agitation","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-09","conditions":"Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease","enrollment":50},{"nctId":"NCT00057681","phase":"PHASE3","title":"Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-02","conditions":"Bipolar Disorder","enrollment":379},{"nctId":"NCT00794625","phase":"PHASE4","title":"Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)","status":"UNKNOWN","sponsor":"Joseph Blader","startDate":"2008-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":270},{"nctId":"NCT01000402","phase":"PHASE4","title":"Juvenile Bipolar Disorder Outpatient Program","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2008-02","conditions":"Bipolar Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":150},{"nctId":"NCT00012558","phase":"NA","title":"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1998-09","conditions":"Bipolar Disorder","enrollment":5000},{"nctId":"NCT00203528","phase":"PHASE4","title":"Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder","status":"COMPLETED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2004-01","conditions":"Substance Abuse, Bipolar Depression","enrollment":30},{"nctId":"NCT00073164","phase":"PHASE2","title":"Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-07","conditions":"Schizophrenia","enrollment":400},{"nctId":"NCT00308360","phase":"PHASE4","title":"Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility","status":"COMPLETED","sponsor":"Nathan Kline Institute for Psychiatric Research","startDate":"1999-09","conditions":"Schizophrenia","enrollment":46},{"nctId":"NCT00177567","phase":"PHASE4","title":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-07","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperidone, divalproex","genericName":"Risperidone, divalproex","companyName":"Nathan Kline Institute for Psychiatric Research","companyId":"nathan-kline-institute-for-psychiatric-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses risperidone (a dopamine antagonist) and divalproex (a histone deacetylase inhibitor and mood stabilizer) together to treat bipolar disorder and related psychiatric conditions. Used for Bipolar disorder (acute mania and maintenance treatment), Schizophrenia with mood instability.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}